How has NVAX's revenue growth performed historically?
NVAX's revenue has grown slower (97.51% per year) than the US Biotechnology industry average (120.44%)
NVAX's revenue has grown faster (97.51% per year) than the US market average (16.77%)
NVAX's revenue growth is accelerating - its growth over the last year (4,991.93%) is above its 5-year compound annual rate (97.51%)
NVAX earnings and revenue history
Current Profit Margin
NVAX Return on equity
NVAX's Return on Equity (-125.7%) shows a company that is not efficient at transforming shareholder equity into returns
NVAX Return on assets
NVAX is generating lower Return on Assets (-40.6%) than the US Biotechnology industry average (-8.58%)
NVAX Return on capital employed
NVAX has gotten more efficient at generating Return on Capital (-42.54%) compared to 3 years ago (-74.54%)
NVAX earnings dates
Next earnings date
Aug 9, 2021
Novavax Earnings & Revenue FAQ
What were NVAX's earnings last quarter?
On May 10, 2021, Novavax (NASDAQ: NVAX) reported Q1 2021 earnings per share (EPS) of -$3.05, up 425.86% year over year. Total Novavax earnings for the quarter were -$222.72 million. In the same quarter last year, Novavax's earnings per share (EPS) was -$0.58.
What was NVAX's earnings growth in the past year?
As of Q2 2021, Novavax's earnings has grown null year over year. Novavax's earnings in the past year totalled -$615.11 million.
On May 10, 2021, Novavax (NASDAQ: NVAX) reported Q1 2021 revenue of $447.23 million up 13,143.38% year over year. In the same quarter last year, Novavax's revenue was $3.38 million.
What was NVAX's revenue growth in the past year?
As of Q2 2021, Novavax's revenue has grown 4,991.93% year over year. This is 4,385.61 percentage points higher than the US Biotechnology industry revenue growth rate of 606.32%. Novavax's revenue in the past year totalled $919.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.